These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1132216)

  • 1. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A
    Clin Ter; 1975 Feb; 72(3):289-95. PubMed ID: 1132216
    [No Abstract]   [Full Text] [Related]  

  • 2. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the formation of H-3-dopa from H-3-tyrosine and determination of the dopa synthesis rate in the fowl and cat adrenal gland under in vivo conditions].
    Hempel K; Männl HF
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 257(4):391-408. PubMed ID: 4232726
    [No Abstract]   [Full Text] [Related]  

  • 4. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H; Ullberg S
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract]   [Full Text] [Related]  

  • 5. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 7. [On the problem of the metabolism of dopamine in the brain of patients with parkinsonism].
    Travenets IA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(10):1505-7. PubMed ID: 6000312
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug therapy of parkinsonism.
    Bianchine JR
    N Engl J Med; 1976 Oct; 295(15):814-8. PubMed ID: 958277
    [No Abstract]   [Full Text] [Related]  

  • 9. Brain dopamine and noradrenaline in 3 Parkinsonians deceased during L-dopa treatment.
    Buscaino GA; Jori A; Campanella G
    Acta Neurol (Napoli); 1972; 27(6):537-44. PubMed ID: 4651485
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    Bartholini G; Pletscher A
    J Pharmacol Exp Ther; 1968 May; 161(1):14-20. PubMed ID: 5648492
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
    Jörg J
    Med Welt; 1979 Nov; 30(46):1740-2. PubMed ID: 537499
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 15. [L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
    Bieniowa A; Kolasa M; Reichowa J
    Przegl Lek; 1976; 33(4):463-7. PubMed ID: 1273343
    [No Abstract]   [Full Text] [Related]  

  • 16. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract]   [Full Text] [Related]  

  • 17. "Catecholamines" in the brain.
    Weiner WJ; Klawans HL
    N Engl J Med; 1970 Feb; 282(9):513-4. PubMed ID: 5411876
    [No Abstract]   [Full Text] [Related]  

  • 18. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 20. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.